1. Home
  2. IGC vs FEDU Comparison

IGC vs FEDU Comparison

Compare IGC & FEDU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • FEDU
  • Stock Information
  • Founded
  • IGC 2005
  • FEDU 2007
  • Country
  • IGC United States
  • FEDU China
  • Employees
  • IGC N/A
  • FEDU N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • FEDU
  • Sector
  • IGC Health Care
  • FEDU
  • Exchange
  • IGC Nasdaq
  • FEDU NYSE
  • Market Cap
  • IGC 20.2M
  • FEDU 21.6M
  • IPO Year
  • IGC N/A
  • FEDU 2017
  • Fundamental
  • Price
  • IGC $0.31
  • FEDU $10.38
  • Analyst Decision
  • IGC Strong Buy
  • FEDU
  • Analyst Count
  • IGC 2
  • FEDU 0
  • Target Price
  • IGC $3.88
  • FEDU N/A
  • AVG Volume (30 Days)
  • IGC 246.3K
  • FEDU 693.0
  • Earning Date
  • IGC 06-27-2025
  • FEDU 07-07-2025
  • Dividend Yield
  • IGC N/A
  • FEDU 22.17%
  • EPS Growth
  • IGC N/A
  • FEDU N/A
  • EPS
  • IGC N/A
  • FEDU 0.05
  • Revenue
  • IGC $1,271,000.00
  • FEDU $34,475,202.00
  • Revenue This Year
  • IGC $15.26
  • FEDU N/A
  • Revenue Next Year
  • IGC $3.41
  • FEDU N/A
  • P/E Ratio
  • IGC N/A
  • FEDU $190.74
  • Revenue Growth
  • IGC N/A
  • FEDU 100.15
  • 52 Week Low
  • IGC $0.25
  • FEDU $3.69
  • 52 Week High
  • IGC $0.50
  • FEDU $22.70
  • Technical
  • Relative Strength Index (RSI)
  • IGC 52.79
  • FEDU 70.57
  • Support Level
  • IGC $0.30
  • FEDU $9.49
  • Resistance Level
  • IGC $0.32
  • FEDU $10.90
  • Average True Range (ATR)
  • IGC 0.01
  • FEDU 0.19
  • MACD
  • IGC 0.00
  • FEDU 0.01
  • Stochastic Oscillator
  • IGC 33.33
  • FEDU 79.68

About IGC IGC Pharma Inc.

IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

About FEDU FOUR SEASONS EDUCATION (CAYMAN) INC SPON ADS EACH REP 10 ORD SHS(R/S)

Four Seasons Education (Cayman) Inc is engaged in the provision of after-school education services for kindergarten, elementary and middle school students. The Company derives its revenue from learning services, tourism services, and learning technology and content solutions. The company is a comprehensive educational enterprise that provides research practice services, educational informatization equipment, high-quality educational resources, and teacher training, as well as a digital publishing business, and continues to expand in educational research and educational informatization.

Share on Social Networks: